Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
David-Dan Nguyen, Raj Satkunasivam, Jethro C.C. Kwong, Bobby Shayegan, Aly-Khan Lalani, Geoffrey T. Gotto, Amanda E. Hird, Andrea Kokorovic, Melissa J. Huynh, Ricardo Rendon, Rodney H. Breau, Antonio Finelli, Neil Fleshner, Girish S. Kulkarni, Alexandre R. Zlotta, Christopher J.D. Wallis
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer
10.1016/j.eururo.2018.07.027 · 2019
10.1200/jco.2022.40.6_suppl.tps285
10.1200/jco.2022.40.6_suppl.tps285 · 2022
Perioperative apalutamide in high-risk localized prostate cancer
10.1056/nejmoa2603878 · 2026
Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy
10.1016/j.urolonc.2019.12.014 · 2020
Heterogeneity in definitions of high-risk prostate cancer and varying impact on mortality rates after radical prostatectomy
10.1016/j.euo.2018.02.004 · 2018
NCCN Guidelines® insights: prostate Cancer, version 3.2024
10.6004/jnccn.2024.0019 · 2024
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era
10.1002/cncr.10657 · 2002
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
10.1001/jama.280.11.969 · 1998
STROBE reporting guidelines for observational studies
10.1001/jamasurg.2021.0528 · 2021
The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival
10.1016/j.juro.2008.09.027 · 2009
Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods
10.1016/j.juro.2007.03.105 · 2007
LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
10.1016/j.annonc.2025.09.102 · 2025
Artificial intelligence predictive model for hormone therapy use in prostate cancer
10.1056/evidoa2300023 · 2023
Performance of a prostate-specific membrane antigen positron emission tomography/computed tomography–derived risk-stratification tool for high-risk and very high-risk prostate cancer
10.1001/jamanetworkopen.2021.38550 · 2021
No additional external references are available.